ADVERTISEMENT
Podcasts
Front-Line Ibrutinib Plus Venetoclax Effective for CLL Irrespective of Patient Age
02/20/2020
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, discusses results from a trial exploring the combination of ibrutinib and venetoclax as first-line treatment for CLL. Dr Nitin presented these results at the 2019 ASH Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement